Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GMAB

Genmab ADR

Dec 10 • 04:00PM ET

21.83

Dollar change -0.28
Percentage change -1.27	%

Healthcare • Biotechnology • Denmark • NASD

Peers: AZN JNJ BMY GSK LLY PFE MRK NVS REGN AMGN

| Held by: IBB FBT FENI AVDE CANC DFIC DFAI APIE ONEQ DFIV

Scroll to Statements

Index	-	P/E	21.03	EPS (ttm)	1.04	Insider Own	0.00%	Shs Outstand	635.24M	Perf Week	0.60%
Market Cap	13.87B	Forward P/E	15.99	EPS next Y	1.36	Insider Trans	-	Shs Float	635.23M	Perf Month	-5.42%
Income	674.78M	PEG	0.84	EPS next Q	0.35	Inst Own	8.28%	Short Float	0.32%	Perf Quarter	-18.94%
Sales	2.87B	P/S	4.83	EPS this Y	28.31%	Inst Trans	0.91%	Short Ratio	1.74	Perf Half Y	-20.10%
Book/sh	7.52	P/B	2.90	EPS next Y	11.61%	ROA	12.34%	Short Interest	2.02M	Perf Year	-32.37%
Cash/sh	4.08	P/C	5.35	EPS next 5Y	24.96%	ROE	14.67%	52W Range	20.34 - 32.88	Perf YTD	-31.44%
Dividend Est.	-	P/FCF	14.72	EPS past 5Y	20.52%	ROI	13.73%	52W High	-33.61%	Beta	0.96
Dividend TTM	-	Quick Ratio	5.15	Sales past 5Y	43.21%	Gross Margin	96.08%	52W Low	7.33%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	5.17	EPS Y/Y TTM	9.82%	Oper. Margin	32.42%	RSI (14)	49.94	Volatility	1.28% 1.59%
Employees	2204	Debt/Eq	0.03	Sales Y/Y TTM	18.04%	Profit Margin	23.49%	Recom	1.89	Target Price	35.95
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-38.16%	Payout	0.00%	Rel Volume	0.85	Prev Close	22.11
Sales Surprise	-3.01%	EPS Surprise	-6.87%	Sales Q/Q	17.81%	Earnings	Nov 06 AMC	Avg Volume	1.16M	Price	21.83
SMA20	2.60%	SMA50	-2.43%	SMA200	-17.62%	Trades		Volume	985,509	Change	-1.27%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-08-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Resumed	Morgan Stanley	Equal-Weight	$31
Aug-20-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-15-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-23-24	Upgrade	BMO Capital Markets	Market Perform → Outperform	$46 → $48
Jan-22-24	Downgrade	Citigroup	Neutral → Sell
Dec-06-23	Upgrade	UBS	Neutral → Buy
Nov-10-23	Upgrade	Deutsche Bank	Hold → Buy
Nov-08-23	Upgrade	DNB Markets	Sell → Buy
Oct-18-23	Initiated	Exane BNP Paribas	Underperform
Sep-06-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-24-23	Initiated	BTIG Research	Buy	$44
Jul-14-23	Initiated	HSBC Securities	Buy
May-31-23	Initiated	UBS	Neutral
May-12-23	Initiated	Morgan Stanley	Underweight
Dec-20-22	Downgrade	Citigroup	Buy → Neutral
Nov-14-22	Initiated	William Blair	Mkt Perform
Nov-11-22	Downgrade	Deutsche Bank	Buy → Hold
Jun-24-22	Initiated	BMO Capital Markets	Market Perform	$34.73
May-02-22	Initiated	Cowen	Market Perform	$38

Show Previous Ratings

Dec-09-24 12:00PM	Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (Business Wire)
Dec-08-24 11:00AM	Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis (Business Wire)
Dec-07-24 07:12PM	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (GlobeNewswire)
Dec-03-24 04:35PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
07:07AM	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
11:06AM	Loading…
Nov-25-24 11:06AM	Genmab to Present at Citi's Global Healthcare Conference (GlobeNewswire)
Nov-21-24 02:48PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Nov-06-24 11:02AM	Genmab Announces Financial Results for the First Nine Months of 2024 (GlobeNewswire)
Nov-05-24 01:11PM	Genmab to Present at Jefferies London Healthcare Conference (GlobeNewswire)
12:00PM	Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-17-24 08:57AM	Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics (Insider Monkey)
Oct-16-24 09:44AM	Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? (Zacks)
Oct-15-24 09:40AM	Is Genmab (GMAB) Stock Undervalued Right Now? (Zacks)
06:25AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2024 (GlobeNewswire)
Oct-04-24 01:55PM	Major Shareholder Announcement (GlobeNewswire)
03:17PM	Loading…
Sep-26-24 03:17PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Sep-15-24 08:45AM	Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial (Business Wire)
Sep-10-24 04:06PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
Aug-30-24 05:49PM	Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers (Insider Monkey)
Aug-26-24 12:26PM	Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-19-24 02:00PM	TEPKINLY (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma (GlobeNewswire)
Aug-16-24 09:00AM	Genmab Announces Changes to its Executive Committee (Business Wire)
Aug-13-24 02:53PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
02:51PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
Aug-08-24 11:03AM	Genmab Announces Financial Results for the First Half of 2024 (GlobeNewswire)
11:00AM	Genmab Updates 2024 Financial Guidance (GlobeNewswire)
Aug-05-24 05:50AM	Genmab Takes Full Control of Acasunlimab Development Program (GlobeNewswire) -7.68%
Jul-17-24 06:25AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2024 (GlobeNewswire)
Jun-28-24 02:00AM	Epcoritamab (TEPKINLY) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma (Business Wire)
Jun-27-24 05:00PM	Completion of Share Buy-back Program (GlobeNewswire)
07:08PM	Loading…
Jun-26-24 07:08PM	EPKINLY (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (Business Wire)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
09:55AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-18-24 02:45PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
Jun-17-24 09:33AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-12-24 03:45PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Jun-11-24 02:50PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
Jun-10-24 10:18AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-06-24 06:19AM	7 Stocks That Could Safely 10X by 2030 (InvestorPlace)
Jun-05-24 12:51PM	Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 09:09AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
09:00AM	Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (Business Wire)
04:45AM	Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC (Clinical Trials Arena)
Jun-02-24 05:30PM	Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma (GlobeNewswire)
Jun-01-24 10:00AM	Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) (Business Wire)
May-27-24 10:16AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-23-24 05:00PM	Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-21-24 11:10AM	Genmab Completes Acquisition of ProfoundBio (Business Wire)
07:19AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-20-24 01:34PM	7 Biotech Stocks That Could Breathe New Life Into Your Portfolio (InvestorPlace)
May-14-24 10:05AM	Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress (Business Wire)
May-13-24 10:09AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-07-24 02:27PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
May-06-24 10:01AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-04-24 12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
May-03-24 12:38PM	Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +7.22%
May-02-24 04:52PM	GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
11:01AM	Genmab Announces Financial Results for the First Quarter of 2024 (GlobeNewswire)
Apr-29-24 06:40PM	TIVDAK (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer (Business Wire)
06:40PM	FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer (Business Wire)
04:24AM	Transactions in Connection with Share Buy-back Program Genmab (GlobeNewswire)
Apr-22-24 03:30AM	Transactions in Connection with Share Buy-back Program Genmab (GlobeNewswire)
Apr-16-24 06:24AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024 (GlobeNewswire)
Apr-15-24 04:07AM	Transactions in Connection with Share Buy-back Program Genmab (GlobeNewswire)
Apr-08-24 05:44AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Apr-03-24 04:02PM	Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover (Investor's Business Daily)
01:05PM	Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media (The Wall Street Journal)
10:06AM	Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio (Investor's Business Daily)
08:48AM	Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio (Investopedia)
07:28AM	Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry (BioPharma Dive)
04:48AM	Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio (The Wall Street Journal)
01:35AM	Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio (Business Wire)
Apr-02-24 03:24AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Mar-25-24 09:31AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Mar-18-24 05:49AM	Completion of share buy-back program (GlobeNewswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 08:16AM	Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire)
Mar-13-24 04:58PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
04:53PM	Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
11:13AM	Passing of Genmab A/S' Annual General Meeting (GlobeNewswire)
Mar-11-24 05:42AM	Transactions in connection with share buy-back program (GlobeNewswire)
Mar-04-24 01:10PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
04:29AM	Transactions in connection with share buy-back program (GlobeNewswire)
Mar-01-24 06:04PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire) +5.47%
Feb-29-24 10:48AM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
Feb-27-24 03:42PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
03:40PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
07:45AM	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (Business Wire)
Feb-26-24 07:45PM	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY ) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (GlobeNewswire)
05:21AM	Transactions in connection with share buy-back program (GlobeNewswire)
Feb-23-24 05:50PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
05:35PM	Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
Feb-19-24 04:40AM	Transactions in connection with share buy-back program (GlobeNewswire)
Feb-15-24 06:00AM	Notice to Convene the Annual General Meeting of Genmab A/S (GlobeNewswire)
Feb-14-24 02:09PM	Genmab Files Annual Report with the U.S. Securities and Exchange Commission (GlobeNewswire)
11:41AM	Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire)
11:02AM	Genmab Publishes 2023 Annual Report (GlobeNewswire)
Feb-02-24 06:45AM	Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer (Business Wire)
Jan-25-24 02:22PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Jan-23-24 06:24AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for 2023 (GlobeNewswire)

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GMAB

Genmab ADR

Upgrade your FINVIZ experience